AURINIA PHARMACEUTICALS INC (AUPH) Stock Analyst Ratings
USA - NASDAQ:AUPH - CA05156V1022 - Common Stock
14.27 USD
+1.1 (+8.35%)
14.3 USD
+0.03 (+0.21%)
ChartMill assigns a Buy % Consensus number of 82% to AUPH. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 11.95. This target is -16.27% below the current price.
AUPH was analyzed by 13 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about AUPH.
In the previous month the buy percentage consensus was at a similar level.
AUPH was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-08-01 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-09-16 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-09-09 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-09-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-02-23 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2024-02-22 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-02-16 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023-09-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-07-06 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-05-03 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-02-23 | RBC Capital | Reiterate | Outperform |
| 2023-01-04 | RBC Capital | Maintains | Outperform |
| 2022-11-07 | HC Wainwright & Co. | Maintains | Buy |
| 2022-11-04 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2022-11-04 | RBC Capital | Maintains | Outperform |
| 2022-11-04 | SVB Leerink | Maintains | Outperform |
| 2022-08-09 | HC Wainwright & Co. | Maintains | Buy |
| 2022-08-08 | Oppenheimer | Maintains | Outperform |
| 2022-05-05 | HC Wainwright & Co. | Maintains | Buy |
| 2022-04-28 | RBC Capital | Maintains | Outperform |
| 2022-03-08 | SVB Leerink | Maintains | Outperform |
| 2022-03-01 | RBC Capital | Maintains | Outperform |
| 2022-02-23 | RBC Capital | Maintains | Outperform |
| 2021-12-10 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2021-11-04 | Oppenheimer | Maintains | Perform |
| 2021-11-04 | SVB Leerink | Maintains | Outperform |
| 2021-11-04 | HC Wainwright & Co. | Maintains | Buy |
| 2021-10-28 | Oppenheimer | Downgrade | Outperform -> Perform |
AURINIA PHARMACEUTICALS INC / AUPH FAQ
What do analysts expect the price target to be for AURINIA PHARMACEUTICALS INC (AUPH)?
13 analysts have analysed AUPH and the average price target is 11.95 USD. This implies a price decrease of -16.27% is expected in the next year compared to the current price of 14.27.
Can you provide the consensus rating for AURINIA PHARMACEUTICALS INC stock?
The consensus rating for AURINIA PHARMACEUTICALS INC (AUPH) is 81.5385 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover AURINIA PHARMACEUTICALS INC (AUPH) stock?
The number of analysts covering AURINIA PHARMACEUTICALS INC (AUPH) is 13.